CN101084309A - 神经元再生 - Google Patents

神经元再生 Download PDF

Info

Publication number
CN101084309A
CN101084309A CNA200480044652XA CN200480044652A CN101084309A CN 101084309 A CN101084309 A CN 101084309A CN A200480044652X A CNA200480044652X A CN A200480044652XA CN 200480044652 A CN200480044652 A CN 200480044652A CN 101084309 A CN101084309 A CN 101084309A
Authority
CN
China
Prior art keywords
seq
gene silencing
molecule
sina
rho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480044652XA
Other languages
English (en)
Chinese (zh)
Inventor
祖贝尔·艾哈迈德
马丁·贝里
安·洛根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuregenix Ltd
Original Assignee
Neuregenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuregenix Ltd filed Critical Neuregenix Ltd
Publication of CN101084309A publication Critical patent/CN101084309A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA200480044652XA 2004-10-22 2004-10-22 神经元再生 Pending CN101084309A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2004/004504 WO2006043014A1 (en) 2004-10-22 2004-10-22 Neuron regeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101157172A Division CN101818150B (zh) 2004-10-22 2004-10-22 神经元再生

Publications (1)

Publication Number Publication Date
CN101084309A true CN101084309A (zh) 2007-12-05

Family

ID=34958935

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480044652XA Pending CN101084309A (zh) 2004-10-22 2004-10-22 神经元再生

Country Status (7)

Country Link
US (1) US7943755B2 (enExample)
EP (1) EP1802755A1 (enExample)
JP (1) JP4704435B2 (enExample)
CN (1) CN101084309A (enExample)
AU (1) AU2004324236B2 (enExample)
CA (1) CA2584921A1 (enExample)
WO (1) WO2006043014A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102326083A (zh) * 2009-02-18 2012-01-18 弗·哈夫曼-拉罗切有限公司 用于抑制神经变性的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014077A2 (en) * 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Rnai modulation of the rho-a gene and uses thereof
CN102666856B (zh) 2009-11-08 2016-04-06 夸克制药公司 定向至RhoA靶基因的双链RNA化合物在制造治疗神经性疼痛的药物中的用途
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410323B1 (en) * 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
CA2398282A1 (en) * 2000-02-11 2001-08-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
AU2002210791A1 (en) * 2000-07-28 2002-02-13 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
JP2007528202A (ja) * 2003-03-28 2007-10-11 株式会社インテレクチャル・プロパティ・コンサルティング 神経再生のための組成物および方法
EP1675949A2 (en) * 2003-10-23 2006-07-05 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102326083A (zh) * 2009-02-18 2012-01-18 弗·哈夫曼-拉罗切有限公司 用于抑制神经变性的方法

Also Published As

Publication number Publication date
US20080253989A1 (en) 2008-10-16
JP4704435B2 (ja) 2011-06-15
AU2004324236A1 (en) 2006-04-27
CA2584921A1 (en) 2006-04-27
EP1802755A1 (en) 2007-07-04
AU2004324236B2 (en) 2010-12-09
US7943755B2 (en) 2011-05-17
WO2006043014A1 (en) 2006-04-27
JP2008516628A (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
TWI465238B (zh) Ｈｓｐ４７表現之調節
US9198981B2 (en) Modulation of angiogenesis
US8410067B2 (en) Inhibition of versican with siRNA and other molecules
KR20090042297A (ko) ＩＯＰ―관련 증상을 치료하기 위한 그렘린의 ＲＮＡｉ 매개 억제
EP2598639A2 (en) Sirna targeting vegfa and methods for treatment in vivo
US20240075053A1 (en) Ror2 inhibitors and use thereof in treating and/or preventing cartilage loss
JP4704435B2 (ja) ニューロン再生
KR20260030856A (ko) 보체 인자 b(cfb) 발현을 억제하기 위한 조성물 및 방법
EP1966368B1 (en) RNAi-MEDIATED INHIBITION OF IGF-1R FOR TREATMENT OF OCULAR ANGIOGENESIS
CN101818150B (zh) 神经元再生
US20060287273A1 (en) Methods and reagents for inhibiting cell proliferation
KR20080044909A (ko) 세포 내로 리보핵산의 전달을 위한 약학 조성물
KR101088764B1 (ko) Ｎｋ１ｒ 단백질 억제제를 포함하는 알코올 의존 예방 및 치료용 조성물
TW202532088A (zh) 抑制亨廷頓蛋白（htt）表達的組合物和方法
KR20200131847A (ko) Ttr 아밀로이드증용 병용 요법
HK1235821B (en) Modulation of hsp47 expression
HK40034234B (en) Ror2 inhibitors and use thereof in treating and/or preventing cartilage loss
HK40034234A (en) Ror2 inhibitors and use thereof in treating and/or preventing cartilage loss
HK40025376B (en) Double-stranded rna molecule targeting ckip-1 and use thereof
Ambati et al. Modulation of Angiogenesis
CA2512492A1 (en) Methods and reagents for inhibiting cell proliferation
HK1117873B (en) Rnai-mediated inhibition of igf-1r for treatment of ocular angiogenesis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071205